Oil-in-water solvent extraction is the most widely used industrial route to long-acting injectable microspheres when the API tolerates dichloromethane. R 202 H is dissolved in dichloromethane at 5–20% w/w; the API is added either as a solution in a co-solvent such as methanol or as a micronized suspension. The organic phase is emulsified into a continuous aqueous phase containing polyvinyl alcohol 0.5–2.0% w/v at pH 4–7. Emulsification is performed with a rotor-stator mixer at tip speed 3–10 m/s, yielding droplets from 20 µm to 80 µm median diameter. The emulsion is transferred into 5–20 volumes of deionized water at 15–25°C and stirred for 2–6 h to extract dichloromethane. The hardened microspheres are collected on a 20 µm sieve, washed, and resuspended in an aqueous vehicle containing mannitol 5% w/v and carboxymethylcellulose sodium 0.5–1.5% w/v before lyophilization at −40°C shelf temperature and 100–200 mTorr chamber pressure for 48–72 h.

The processing step that most often requires design-of-experiments control at scale is solvent extraction. Rapid extraction with more than 15 volumes of water increases surface porosity and raises the 24 h burst for low-molecular-weight PLDLA; slow extraction below 5 volumes produces denser surfaces but extends cycle time and can leave residual dichloromethane above the 600 ppm limit in ICH Q3C for a 10 g daily dose. Residual dichloromethane is measured by headspace gas chromatography according to USP <467>. Encapsulation efficiency is determined by reversed-phase HPLC using USP <621> conditions, with typical acceptance from 80% to 95%. In vitro release for a microsphere suspension is conducted in USP Apparatus 4 with phosphate-buffered saline at 37°C and pH 7.4; the release interval may extend from 7 days to 90 days depending on drug loading and polymer concentration. Terminal sterilization by gamma irradiation at 25–40 kGy must be qualified for lot-specific shift in inherent viscosity measured by ISO 1628-1 using 0.1% w/v chloroform at 25°C.

Acid-terminated R 202 H is hygroscopic. For solvent-based processing, moisture uptake above 0.5% w/w can accelerate backbone hydrolysis during storage and reduce effective molecular weight before emulsification. The polymer should be vacuum-dried at 25–30°C for 12–24 h before use when opened above 60% relative humidity. The acid end groups also make R 202 H incompatible with basic peptides that are unstable in a microenvironment pH below 3 during late-stage polymer degradation.

What Limits Phase-Inversion Kinetics in N-Methyl-2-pyrrolidone Depots?

In situ forming implants based on R 202 H use N-methyl-2-pyrrolidone or dimethyl sulfoxide at polymer concentrations from 20% w/w to 45% w/w. The formulation is injected through a 21 G or 23 G needle; after injection, the water-miscible solvent exchanges with interstitial fluid and the polymer precipitates as a depot. NMP is fully miscible with water and has a viscosity of 1.65 mPa·s at 25°C, while DMSO has a viscosity of 1.99 mPa·s at 25°C. The faster solvent exchange of NMP produces a more open and porous structure at polymer concentrations below 25% w/w, which typically increases the 24 h release. Raising the polymer concentration from 20% w/w to 40% w/w shifts phase inversion from instantaneous demixing to delayed demixing and yields a denser skin; this is a common method for suppressing burst without changing the API load.

Residual solvent is the primary regulatory constraint. ICH Q3C classifies NMP as Class 2 with a permitted daily exposure of 5.3 mg/day and a concentration limit of 530 ppm for a 10 g daily dose. DMSO is Class 3 and is limited by the 50 mg/day PDE under ICH Q3C. If the product is filled as a liquid, sterilizing-grade filtration through 0.2 µm polyethersulfone is feasible only when the dynamic viscosity remains below 5 Pa·s at 25°C; above 35% w/w, R 202 H/NMP solutions often exceed this threshold and require large membrane areas or pre-filtration through 0.45 µm. Aseptic filling in a Class A isolator is the preferred route for terminally unstable liquid depots.

The acid-terminated backbone creates a sharp operational boundary for acid-labile APIs. During late-stage degradation, the pH inside a PLDLA depot can fall to 3 or below, which is incompatible with peptides containing asparagine or aspartic acid residues prone to deamidation. Syringeability is measured by force versus displacement using a texture analyzer fitted with a 21 G needle and a crosshead speed of 1 mm/s; force above 25 N is generally considered a rejection boundary for self-administration. Because R 202 H has a low inherent viscosity near 0.2 dL/g, the syringeability limit is more often reached by polymer concentration than by molecular weight.

When sub-200 nm particles are required for intravenous or lymphatic delivery, R 202 H is processed by nanoprecipitation rather than emulsion solvent evaporation. The polymer is dissolved at 2–10 mg/mL in acetone or tetrahydrofuran and injected into an aqueous non-solvent containing Poloxamer 188 0.1–0.5% w/v or polyvinyl alcohol 0.25–1.0% w/v. Acetone is preferred for injectable nanosuspensions because it is a Class 3 solvent under ICH Q3C with a 50 mg/day permitted daily exposure; THF is Class 2 with a 7.2 mg/day PDE and a concentration limit of 720 ppm. The resulting mean particle size is governed by polymer concentration, phase ratio, and aqueous-phase temperature; for R 202 H, increasing the aqueous phase from 4°C to 25°C can shift the z-average diameter by 20–50 nm due to solvent diffusion kinetics. Particle size and polydispersity are measured by dynamic light scattering according to ISO 22412. The suspension is concentrated by tangential flow filtration using a 100 kDa regenerated cellulose membrane and diafiltered against water for injection to reduce acetone below 5000 ppm.

Sterile filtration is the terminal unit operation only when the z-average diameter is below 180 nm and the polydispersity index is below 0.15. A 0.2 µm polyethersulfone membrane is used with constant transmembrane pressure below 1.0 bar; filter capacity for R 202 H nanosuspensions is generally lower than for solid lipid nanoparticles because of the polymer’s tendency to form a fouling layer. If the particle size exceeds 200 nm, aseptic processing or gamma irradiation at 25 kGy is required. The final lyophilized cake contains trehalose or sucrose at 2–5% w/v as cryoprotectant. Endotoxin in the reconstituted suspension must be below 0.5 EU/mL by USP <85>, and subvisible particulates must comply with USP <788> small-volume injection limits of 6000 particles/container for particles ≥10 µm and 600 particles/container for particles ≥25 µm. Drug loading in nanoprecipitated R 202 H is typically limited to <10% w/w; higher loading promotes surface crystallization and increases the initial release rate.

Spray Drying of Low-IV PLDLA Demands Separate Control of Feed Viscosity and Cyclone Exit Humidity

For poorly water-soluble APIs requiring amorphous stabilization, R 202 H is evaluated as a low-molecular-weight carrier in spray-dried dispersions. A feed solution is prepared at 5–15% w/w in acetone or a mixture of acetone and ethanol; feed viscosity remains below 50 mPa·s at 25°C to permit atomization through a two-fluid nozzle. Inlet temperature is set between 50°C and 70°C, and the cyclone exit temperature is maintained at 30–45°C. Because R 202 H has a glass transition near 50°C measured by DSC according to ISO 11357-2, outlet temperatures above 45°C can cause particle agglomeration on the cyclone wall. Cyclone exit relative humidity below 10% is required to prevent water uptake and collapse of the amorphous matrix.

The low acid number and low molecular weight of R 202 H reduce viscosity for spray drying but also reduce the kinetic stabilization of amorphous API. For highly lipophilic APIs with a crystallization tendency, a higher-molecular-weight PLDLA or PLGA is combined with R 202 H at 10–30% w/w of the total polymer to tune release without raising feed viscosity beyond the atomizer limit. Residual acetone is measured by gas chromatography according to USP <467>; the limit for acetone is 5000 ppm under ICH Q3C. Secondary drying under vacuum at 40°C and <10 mbar for 24–48 h is used to achieve moisture below 0.5% w/w. The dried dispersion is stored with molecular sieve desiccant in aluminum foil pouches; moisture uptake above 1.0% w/w depresses the glass transition and causes phase separation that is detectable by modulated DSC according to ISO 11357-2.

Published stability data for R 202 H in spray-dried amorphous dispersions with Biopharmaceutics Classification System Class II APIs is limited. The formulation scientist must run a factorial design with feed solids content, inlet temperature, and post-drying residual moisture as independent variables, because the low glass transition temperature makes the space between acceptable drying and re-agglomeration narrower than for PLDLA grades above 0.5 dL/g.

Intravitreal microspheres impose the narrowest particle-size envelope among R 202 H applications. The suspension must pass through a 27 G or 25 G thin-wall needle; a 27 G needle has a nominal inner diameter of 0.21 mm. Microspheres with a Dv90 above 80 µm are considered a syringeability risk. The preferred size distribution is a Dv50 of 10–40 µm with Dv10 above 5 µm to ensure slow clearance from the vitreous. R 202 H microspheres for intravitreal use are not terminally sterilized without qualification because gamma irradiation at 25 kGy can reduce inherent viscosity and shift release. Aseptic processing is preferred; the polymer is filtered before lyophilization or sterilized by irradiation below 15 kGy when release data show no statistically significant change. Sterility is confirmed by USP <71>, and the ocular endotoxin limit is commonly set at 0.5 EU/mL by USP <85>, although the approved limit may be lower for a 50 µL intravitreal dose volume.

The final reconstituted suspension contains microspheres dispersed in sodium hyaluronate 0.1–0.3% w/v or a poloxamer vehicle at 0.5–2.0% w/v. Suspension viscosity is adjusted to allow settling within minutes for injection but slow enough to prevent needle clogging. In vitro release testing for intravitreal microspheres uses USP Apparatus 7 or a small-volume dissolution chamber with simulated vitreous fluid at 37°C. Because the vitreous volume is only 4–5 mL in humans, release media volumes are often limited to 1–2 mL to avoid sink saturation. Residual dichloromethane is controlled to 600 ppm under ICH Q3C, but intraocular products frequently have tighter internal limits because of the small dose volume and high local sensitivity.

The largest technical bottleneck is not microsphere formation but terminal particle-size de-agglomeration. R 202 H microspheres lyophilized without sufficient cryoprotectant form irreversible aggregates that cannot be fully redispersed with a vortex mixer or an ultrasonic bath. Particle size is verified by laser diffraction according to ISO 13320 after reconstitution; if the Dv90 shifts by more than 10% relative to the pre-lyophilization suspension, the mannitol or trehalose concentration must be increased.

When Melt Extrusion Is Used for Subcutaneous Rod Implants

When melt extrusion is selected, lot-specific moisture content must be confirmed at <0.1% w/w by Karl Fischer titration according to ISO 15512 before compounding. R 202 H is pre-dried under vacuum at 40°C for 12–24 h; the acid-terminated backbone undergoes hydrolytic degradation above 100°C if moisture is present. A co-rotating twin-screw extruder with L/D ratio between 25:1 and 40:1 is used with barrel temperatures from 80°C to 120°C. Screw speed is maintained between 50 rpm and 200 rpm. The melt strand is drawn through a die at 90°C or below; the low inherent viscosity near 0.2 dL/g reduces melt strength, and higher die temperatures lead to strand breakage. The extrudate is cut into rods of 1.0–2.5 mm diameter and 1–3 cm length, then packaged under nitrogen.

Melt extrusion of low-IV PLDLA alone is operationally limited; many subcutaneous rod formulations use R 202 H as a flow modifier or release-modifying minor component with a higher-IV PLDLA or PLGA. At 10–30% w/w of the total polymer, R 202 H lowers melt viscosity and facilitates API dispersion without dominating the mechanical strength of the rod. Post-extrusion molecular weight is measured by GPC according to ISO 16014-3; a molecular weight loss above 15% relative to the pre-extrusion material is a rejection boundary for release prolongation. In vitro release is measured using USP Apparatus 7 with reciprocating holders in phosphate-buffered saline at 37°C and pH 7.4. Because the rods are implanted subcutaneously, the degradation environment is not sink-limited; the release medium volume is set to maintain API solubility below 10% of saturation for the tested interval.

Published data for this specific low-IV acid-terminated PLDLA in extruded rods is limited. The extrusion window is narrower than for PLDLA grades above 0.5 dL/g; a design-of-experiments matrix with die temperature, screw speed, and moisture content is required to separate process-induced degradation from formulation effects.